1. Home
  2. ACR vs HURA Comparison

ACR vs HURA Comparison

Compare ACR & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ACR

ACRES Commercial Realty Corp.

HOLD

Current Price

$17.62

Market Cap

146.1M

Sector

Real Estate

ML Signal

HOLD

Logo TuHURA Biosciences Inc.

HURA

TuHURA Biosciences Inc.

HOLD

Current Price

$2.27

Market Cap

160.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACR
HURA
Founded
2005
2009
Country
United States
United States
Employees
4
22
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
146.1M
160.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ACR
HURA
Price
$17.62
$2.27
Analyst Decision
Buy
Strong Buy
Analyst Count
1
2
Target Price
$24.50
$9.50
AVG Volume (30 Days)
42.5K
731.4K
Earning Date
04-30-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$19.59
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.61
$0.41
52 Week High
$24.61
$3.90

Technical Indicators

Market Signals
Indicator
ACR
HURA
Relative Strength Index (RSI) 49.27 46.60
Support Level $17.34 $2.14
Resistance Level $19.64 $2.80
Average True Range (ATR) 0.46 0.19
MACD 0.10 -0.02
Stochastic Oscillator 57.89 31.00

Price Performance

Historical Comparison
ACR
HURA

About ACR ACRES Commercial Realty Corp.

ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding, and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralized debt obligations, and private equity investments mainly issued by financial institutions.

About HURA TuHURA Biosciences Inc.

TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.

Share on Social Networks: